Austin · TX, USA · founded 2017 · https://www.macromoltek.com
Diligence memoA one-page analyst read on Macromoltek — recommendation, valuation, rhythm, risks.→Macromoltek: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Computational antibody design
Macromoltek: Revolutionizing antibody design. Description: Macromoltek, a computational de novo drug design company, rapidly produces accurate and credible antibody designs. We have built a proprietary platform that enables design against difficult targets inaccessible by traditional methods and have are already designing antibodies for large biopharmas and smaller biotechs.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 8525 companies in this sector. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 96% of sector peers (real $). Modeled value above 96% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Macromoltek is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Nabla Bio We use AI to design antibodies for intractable diseases | Biotech | — | — | 77% |
| b12 Labs Chemical Copilot for Pharma and Biotech | Biotech | — | — | 77% |
| 1910 Multimodal AI Platform for Modality Agnostic Drug Discovery™ | Biotech | — | — | 76% |
| 10x Science The AI-native platform for next-generation protein characterization. | Biotech | — | — | 76% |
| Menten AI Menten AI designs peptide and protein therapeutics using quantum… | Biotech | — | — | 75% |
| Synthio Labs Agentic AI platform for Pharma GTM teams | Biotech | — | — | 75% |
| Lavo Life Sciences AI for drug formulation | Biotech | — | — | 75% |
| Delineate Agents for Accelerated Clinical Trial Design | Biotech | — | — | 74% |
See where Macromoltek sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Macromoltek, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.